Overview

Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
This study investigated whether initiation of everolimus together with reduction of calcineurin inhibitors (CNI) in maintenance heart or lung transplant patients with renal impairment would improve renal function.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Azathioprine
Calcineurin Inhibitors
Everolimus
Immunosuppressive Agents
Mycophenolate mofetil
Mycophenolic Acid
Sirolimus